7UX.F SPAGO NANOMEDICAL AB

Healthcare Biotechnology Frankfurt Exchange
0.0036 EUR
Close of Nov 11, 2026
0.0016 0.0110
Market cap
EUR 2.87M
P/E
-
P/B
1.05x
ROE
-89.2%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 7UX.F undervalued?

Graham number

The Graham number of SPAGO NANOMEDICAL AB cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

SPAGO NANOMEDICAL AB fundamental analysis

No fundamental analysis for SPAGO NANOMEDICAL AB yet.

SPAGO NANOMEDICAL AB stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About SPAGO NANOMEDICAL AB

Spago Nanomedical AB (publ), a nanomedicine company, engages in the development projects based on a platform of polymeric materials for diagnosis and treatment of life-threatening and debilitating diseases in Sweden. Its products include SpagoPix (SN132D), an MRI contrast agent, which is under Phase I development stage for the treatment of breast cancer, and under Phase II development stage for the treatment of liver and pancreas cancer, as well as offers Tumorad (SN201), a …

Full company profile